A double-blind placebo controlled randomized phase III trial of Fulvestrant and Ipatasertib as treatment for advanced HER-2 Negative and Estrogen Receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor

  • Sabanathan, Dhanusha (Primary Chief Investigator)
  • Chapman, Nicola (Chief Investigator)

Project: Research

Project Details

Short titleCCTG MA.40/ BCT 2101
AcronymFINER
StatusActive
Effective start/end date2/02/2230/09/25